New onset executive function difficulties at menopause: a possible role for lisdexamfetamine
New onset executive function difficulties at menopause: a possible role for lisdexamfetamine
复制标题
DOI：
10.1007/s00213-015-3953-7
复制
发表时间：
2015-08-01
影响因子：
3.4
通讯作者：
Brown, Thomas E.
中科院分区：
文献类型：
--
作者：
Epperson, C. Neill;Shanmugan, Sheila;Brown, Thomas E.
认知能力下降的报告，特别是在执行功能（EFs）领域，在更年期妇女中很常见。本研究旨在确定精神兴奋剂利地安非他明（LDX）对报告新发EF的绝经妇女主客观认知功能的影响。在这项双盲、安慰剂对照、交叉研究中，32名健康的围绝经期和绝经后早期妇女使用布朗注意缺陷障碍量表（badd）测量中年发作的执行功能困难，给予LDX 40-60毫克/天，持续4周。终生ADHD的诊断是排他性的。badd总分和子量表得分以及在言语记忆和工作记忆任务上的表现是我们感兴趣的结果。分析显示，LDX治疗对badd总评分（p = 0.0001）和5个badd亚量表中的4个（均p < 0.004）的显著影响优于安慰剂。LDX治疗也显著改善了延迟段落回忆（p = 0.018），但治疗对其他认知测量没有显著影响。当女性服用LDX时，收缩压（p = 0.017）和心率显著增加（p = 0.006），但平均而言仍在正常范围内。LDX 40- 60mg /天耐受性良好，改善了健康绝经妇女执行功能的主观测量和延迟言语回忆的客观测量。
Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women.This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints.Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40-60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest.Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range.LDX 40-60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.